Diagnostics (Mar 2022)

Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis

  • Angela Santoro,
  • Antonio Travaglino,
  • Frediano Inzani,
  • Patrizia Straccia,
  • Damiano Arciuolo,
  • Michele Valente,
  • Nicoletta D’Alessandris,
  • Giulia Scaglione,
  • Giuseppe Angelico,
  • Alessia Piermattei,
  • Federica Cianfrini,
  • Antonio Raffone,
  • Gian Franco Zannoni

DOI
https://doi.org/10.3390/diagnostics12030633
Journal volume & issue
Vol. 12, no. 3
p. 633

Abstract

Read online

Background: chemotherapy response score (CRS) is widely used to assess the response of ovarian high-grade serous carcinoma (HGSC) to chemotherapy and is based on pathological examination of omental specimens. We aimed to assess the prognostic value of CRS assessed on the uterine adnexa. Methods: a systematic review and meta-analysis were performed by searching three electronic databases from 2015 inception to September 2021. We included all studies reporting either hazard ratio (HR) with 95% confidence interval (CI) for progression-free survival (PFS) or primary PFS data, for both adnexal and omental CRS in HGSC. HRs with 95% CI were extracted and pooled by using a significant p-value p p < 0.001). Statistical heterogeneity was 0% in both analyses. Conclusions: adnexal CRS significantly stratifies PFS in HGSC and might be used when omental CRS is not assessable.

Keywords